Evidence map›Paper›PMID 34671193›Full record

ArticleInternational journal of biological sciences2021

Cancer-associated fibroblasts-derived exosomal miR-3656 promotes the development and progression of esophageal squamous cell carcinoma via the ACAP2/PI3K-AKT signaling pathway.

Yuan Jin, Qilin Meng, Bihui Zhang, Chen Xie, Xue Chen, Baoqing Tian, Jiakang Wang, Tsung-Chieh Shih, Yibo Zhang, Jieqiong Cao and 5 more

Open access · goldAbstract read
In one paragraph

Article in International journal of biological sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Exosomes in esophageal cancer: function and therapeutic prospects.Medical oncology (Northwood, London, England) · 2024
    Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Yuan JinDepartment of Cell Biology, College of Life Science and Technology, Jinan University, Guangzhou 510632, P. R. China.
Qilin MengDepartment of Cell Biology, College of Life Science and Technology, Jinan University, Guangzhou 510632, P. R. China.
Bihui ZhangDepartment of Cell Biology, College of Life Science and Technology, Jinan University, Guangzhou 510632, P. R. China.
Chen XieDepartment of Cell Biology, College of Life Science and Technology, Jinan University, Guangzhou 510632, P. R. China.
Xue ChenDepartment of Cell Biology, College of Life Science and Technology, Jinan University, Guangzhou 510632, P. R. China.
Baoqing TianDepartment of Cell Biology, College of Life Science and Technology, Jinan University, Guangzhou 510632, P. R. China.
Jiakang WangCancer Center of Guangzhou Medical University, Guangzhou 510090, P. R. China.
Tsung-Chieh ShihDepartment of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, California, USA.
Yibo ZhangDepartment of Cell Biology, College of Life Science and Technology, Jinan University, Guangzhou 510632, P. R. China.
Jieqiong CaoDepartment of Cell Biology, College of Life Science and Technology, Jinan University, Guangzhou 510632, P. R. China.
Yiqi YangDepartment of Cell Biology, College of Life Science and Technology, Jinan University, Guangzhou 510632, P. R. China.
Size ChenOncology Department, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510080, P. R. China.
Xinyuan GuanDepartment of Clinical Oncology, University of Hong Kong, Hong Kong, P. R. China.
Xiaojia ChenDepartment of Cell Biology, College of Life Science and Technology, Jinan University, Guangzhou 510632, P. R. China.
An HongDepartment of Cell Biology, College of Life Science and Technology, Jinan University, Guangzhou 510632, P. R. China.
Key Laboratory of Guangdong Province · CNJinan University · CNChinese University of Hong Kong · CNFirst Affiliated Hospital of Guangdong Pharmaceutical University · CNShandong Tumor Hospital · CNUniversity of California, Davis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Esophageal squamous cell carcinoma (ESCC) is one of the most common gastrointestinal tumors, accounting for almost half a million deaths per year. Cancer-associated fibroblasts (CAFs) are the major constituent of the tumor microenvironment (TME) and dramatically impact ESCC progression. Recent evidence suggests that exosomes derived from CAFs are able to transmit regulating signals and promote ESCC development. In this study, we compared different the component ratios of miRNAs in exosomes secreted by CAFs in tumors and with those from normal fibroblasts (NFs) in precancerous tissues. The mRNA level of hsa-miR-3656 was significantly upregulated in the former exosomes. Subsequently, by comparing tumor cell development in vitro and in vivo, we found that the proliferation, migration and invasion capabilities of ESCC cells were significantly improved when miR-3656 was present. Further target gene analysis confirmed ACAP2 was a target gene regulated by miR-3656 and exhibited a negative regulatory effect on tumor proliferation. Additionally, the downregulation of ACAP2 triggered by exosomal-derived miR-3656 further promotes the activation of the PI3K/AKT and β-catenin signaling pathways and ultimately improves the growth of ESCC cells both in vitro and in xenograft models. These results may represent a potential therapeutic target for ESCC and provide a new basis for clinical treatment plans.

Indexed as

AnimalsDisease ProgressionEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaExosomesFemaleFibroblastsHigh-Throughput Nucleotide SequencingHumansMembrane ProteinsMiceMice, Inbred BALB CMicroRNAsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionACAP2 protein, humanMembrane ProteinsMicroRNAsMIRN3656 microRNA, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktACAP2Cancer-associated Fibroblast (CAF)Esophageal Squamous Cell Carcinoma (ESCC)ExosomeMicroRNA miR-3656

Identifiers

PMID34671193
PMCPMC8495391
OpenAlexW3196295376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.